search
Back to results

The Effect of Nebivolol on Insulin Sensitivity

Primary Purpose

Hypertension

Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Nebivolol
Atenolol
Sponsored by
Imperial College London
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension focused on measuring blood pressure, insulin sensitivity, beta blockers, randomised double blind crossover trial

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Males or females aged 18 or above Blood pressure that meets any of the three following criteria: BP should be <140/85 mmHg on a maximum of two anti-hypertensive drugs Exclusion Criteria: contraindications to beta-blockade contraindications to thiazide use if there was a history of asthma, diabetes, heart failure, bradycardia, atrial fibrillation, AV conduction disturbances concurrent treatment with verapamil & dilitiazem childbearing women compelling indication for treatment with a beta blocker any condition that will interfere with the treatment or the patient's ability to complete the study

Sites / Locations

  • Imperial College London

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

atenolol 25mg daily

nebivolol 2.5mg daily

Arm Description

atenolol 25mg daily

nebivolol 2.5mg daily

Outcomes

Primary Outcome Measures

Insulin Sensitivity Index (ISI)
Patients were asked to fast for a minimum of 12 hours prior to each oral glucose tolerance test (OGTT). Venous blood was withdrawn for insulin and glucose analysis, 15 minutes and immediately prior to, and 30, 60, 90 and 120 minutes following an oral glucose load. For each OGTT, the Insulin Sensitivity Index (ISI) was calculated using the standard method for oral glucose tolerance testing. For each OGTT, the Insulin Sensitivity Index (ISI) was calculated using the standard method for oral glucose tolerance testing.

Secondary Outcome Measures

24 Hour Systolic Blood Pressure
The 24-h Ambulatory Blood Pressure Monitoring (ABPM) was recorded at the beginning and end of each beta-blocker treatment period. BP was automatically recorded for 24 h at 30 min intervals. The time periods from 0700h to 2200h and from 2200h to 0700h were defined as daytime and night-time, respectively.
Total Cholesterol
Fasting blood samples were taken at the beginning and end of each treatment period.
HbA1c
Fasting blood samples were taken at the beginning and end of each treatment period.
BMI
Body weights and heights were taken at the beginning and end of each treatment period.

Full Information

First Posted
July 29, 2005
Last Updated
November 21, 2019
Sponsor
Imperial College London
Collaborators
Foundation for Circulatory Health
search

1. Study Identification

Unique Protocol Identification Number
NCT00125853
Brief Title
The Effect of Nebivolol on Insulin Sensitivity
Official Title
A Trial to Compare the Effects of Nebivolol Versus Atenolol on Various Cardiovascular Measurements Including Insulin Sensitivity
Study Type
Interventional

2. Study Status

Record Verification Date
November 2019
Overall Recruitment Status
Completed
Study Start Date
July 2006 (Actual)
Primary Completion Date
January 2009 (Actual)
Study Completion Date
January 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Imperial College London
Collaborators
Foundation for Circulatory Health

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to conduct a randomised trial to compare the insulin sensitivity, 24 hour blood pressure profile, and tolerability of nebivolol plus a thiazide-like diuretic versus atenolol plus a thiazide-like diuretic.
Detailed Description
Retrospective studies of treated hypertensive cohorts have strongly implicated beta blocker therapy as increasing the risk of developing new-onset diabetes. This has led to the latest British Hypertension Society guidelines advising caution when using beta blockers particularly in combination with thiazide-like diuretics. However the National Institute of Clinical Excellence recommends beta-blocker + thiazide combinations as the treatment of choice in patients who are not at increased risk of developing diabetes. Nebivolol is a newer class of beta blocker. Some studies in diabetic hypertensive patients have suggested that nebivolol does not impair insulin sensitivity. The aim of this study is to compare the effect on insulin sensitivity of nebivolol versus atenolol, both in combination with a thiazide-like diuretic, in a group of non-diabetic hypertensive patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
blood pressure, insulin sensitivity, beta blockers, randomised double blind crossover trial

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
Participant
Allocation
Randomized
Enrollment
54 (Actual)

8. Arms, Groups, and Interventions

Arm Title
atenolol 25mg daily
Arm Type
Experimental
Arm Description
atenolol 25mg daily
Arm Title
nebivolol 2.5mg daily
Arm Type
Active Comparator
Arm Description
nebivolol 2.5mg daily
Intervention Type
Drug
Intervention Name(s)
Nebivolol
Intervention Description
Nebivolol 2.5mg daily
Intervention Type
Drug
Intervention Name(s)
Atenolol
Intervention Description
Atenolol 25mg daily
Primary Outcome Measure Information:
Title
Insulin Sensitivity Index (ISI)
Description
Patients were asked to fast for a minimum of 12 hours prior to each oral glucose tolerance test (OGTT). Venous blood was withdrawn for insulin and glucose analysis, 15 minutes and immediately prior to, and 30, 60, 90 and 120 minutes following an oral glucose load. For each OGTT, the Insulin Sensitivity Index (ISI) was calculated using the standard method for oral glucose tolerance testing. For each OGTT, the Insulin Sensitivity Index (ISI) was calculated using the standard method for oral glucose tolerance testing.
Time Frame
Baseline, 15, 30, 60, 90, 120m following oral glucose load, at baseline and at the end of each phase(8 weeks treatment
Secondary Outcome Measure Information:
Title
24 Hour Systolic Blood Pressure
Description
The 24-h Ambulatory Blood Pressure Monitoring (ABPM) was recorded at the beginning and end of each beta-blocker treatment period. BP was automatically recorded for 24 h at 30 min intervals. The time periods from 0700h to 2200h and from 2200h to 0700h were defined as daytime and night-time, respectively.
Time Frame
Before and after 8 weeks of treatment
Title
Total Cholesterol
Description
Fasting blood samples were taken at the beginning and end of each treatment period.
Time Frame
Before and after 8 weeks of treatment
Title
HbA1c
Description
Fasting blood samples were taken at the beginning and end of each treatment period.
Time Frame
Before and after 8 weeks of treatment
Title
BMI
Description
Body weights and heights were taken at the beginning and end of each treatment period.
Time Frame
Before and after 8 weeks of treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Males or females aged 18 or above Blood pressure that meets any of the three following criteria: BP should be <140/85 mmHg on a maximum of two anti-hypertensive drugs Exclusion Criteria: contraindications to beta-blockade contraindications to thiazide use if there was a history of asthma, diabetes, heart failure, bradycardia, atrial fibrillation, AV conduction disturbances concurrent treatment with verapamil & dilitiazem childbearing women compelling indication for treatment with a beta blocker any condition that will interfere with the treatment or the patient's ability to complete the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Neil R Poulter
Organizational Affiliation
Imperial College London
Official's Role
Principal Investigator
Facility Information:
Facility Name
Imperial College London
City
Paddington
State/Province
London
ZIP/Postal Code
W2 1PG
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

The Effect of Nebivolol on Insulin Sensitivity

We'll reach out to this number within 24 hrs